| Biomarker ID | 1632 |
| PMID | 31031850 |
| Year | 2019 |
| Biomarker | BUB1B |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.116 |
| Effect on Pathways | Pathways include: APC/C- and Cdc20-mediated degradation of Nek2A, Inactivation of APC/C via direct inhibition of the APC/C complex, Polo-like kinase 1 (PLK1) pathway, APC/C-mediated degradation of cell cycle proteins, M phase pathway |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 498 cases from TCGA-PRAD were analysed along with 52 normal prostate controls were selected for the analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.6673 |
| Accuracy | NA |
| Level Of Significance | p < 0.0001 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |